Bioequivalence Study in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Hypertension

Interventions

DRUG

Candesartan cilexetil

Formulation:Oral suspensionStrength:1 mg/mLDose: 32 mg, single dose

DRUG

Candesartan cilexetil

Formulation:Oral suspensionStrength:1.6 mg/mLDose: 32 mg, single dose

Trial Locations (1)

Research Site, Harrow